Utility-Based Optimal Phase II/III Drug Development Planning

---

Documentation for package ‘drugdevelopR’ version 1.0.2

• DESCRIPTION file.
• User guides, package vignettes and other documentation.
• Package NEWS.

Help Pages

optimal_bias	Optimal phase II/III drug development planning for time-to-event endpoints when discounting phase II results
optimal_bias_binary	Optimal phase II/III drug development planning when discounting phase II results with binary endpoint
optimal_bias_normal	Optimal phase II/III drug development planning when discounting phase II results with normally distributed endpoint
optimal_binary	Optimal phase II/III drug development planning with binary endpoint
optimal_multiarm	Optimal phase II/III drug development planning for multi-arm programs with time-to-event endpoint
optimal_multiarm_binary	Optimal phase II/III drug development planning for multi-arm programs with binary endpoint
optimal_multiarm_normal	Optimal phase II/III drug development planning for multi-arm programs with normally distributed endpoint
optimal_multiple_normal	Optimal phase II/III drug development planning for programs with multiple normally distributed endpoints
optimal_multiple_tte	Optimal phase II/III drug development planning for programs with multiple time-to-event endpoints
optimal_multitrial	Optimal phase II/III drug development planning where several phase III trials are performed for time-to-event endpoints
optimal_multitrial_binary	Optimal phase II/III drug development planning where several phase III trials are performed
optimal_multitrial_normal	Optimal phase II/III drug development planning where several phase III trials are performed
optimal_normal	Optimal phase II/III drug development planning with normally distributed endpoint
optimal_tte	Optimal phase II/III drug development planning with time-to-event endpoint